Informationen på dette website er kun beregnet til Sundhedspersoner i Danmark

Søg

Menu

Close

Log indLog udLægemidlerTerapiområderPfizerConnectPfizerConnectArrangementerMaterialerEfteruddannelse

Information om bivirkningsindberetning findes nederst på denne side

AboutAlopecia AreataLITFULO Mechanism of ActionSALT EvaluationEfficacyALLEGRO-2b/3 Study OverviewScalp Hair ResponsePatient-reported OutcomesEyebrow & Eyelash ResponseBefore & After ImagesSafetyALLEGRO-2b/3 Adverse ReactionsAdditional Safety ConsiderationsGetting StartedDosingScreening & MonitoringSetting Patient ExpectationsResourcesMaterialsVideos
ALLEGRO-2b/3 Adverse ReactionsThe most frequently reported adverse reactions with LITFULO are diarrhoea (9.2%), acne (6.2%), upper respiratory tract infections (6.2%), urticaria (4.6%), rash (3.8%), folliculitis (3.1%), and dizziness (2.3%).[2] 
Scroll left to view table
Table made by Pfizer based on table 3 and table 4 in ref. 3
  • 2 (1.5%) patients treated with LITFULO 50 mg and 2 (1.5%) patients who received placebo were discontinued from the study due to adverse reactions[3] 
Treatment for 48 weeks demonstrated an acceptable safety profil in adolescents[4] References:1. King B, Zhang X, Harcha WG, et al. Supplement to: Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial. Lancet. April 13, 2023. doi:10.1016/S0140-6736(23)00222-2 2.LITFULO (ritlecitinib) SmPC. 3.King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial. Lancet. 2023;401(10387):1518-1529. doi:10.1016/S0140-6736(23)00222-2. Erratum in: Lancet. 2023 Jun 10;401(10392):1928. 4.Hordinsky M. Pediatr Dermatol. 2023 Nov-Dec;40(6);1003-1009_Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial
 Indication Litfulo® (ritlecitinib):
 Litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.[Litfulo SmPC] 
 Litfulo pligttekst
Safety Get appropriate patients started on LITFULO today Getting started Loading

Bivirkninger skal indberettes. Hvis du vil rapportere en bivirkning, kan du kontakte Pfizer på e-mail: [email protected]

 

PfizerPro kontoPfizerPro konto

Få adgang til information, materialer, efteruddannelse samt modtag kommunikation om Pfizers lægemidler og vacciner.

Log indRegisterMin profilLog ud

Informationen på dette website er kun beregnet til Sundhedspersoner i Danmark.

Denne hjemmeside er udarbejdet til dig af Pfizer Danmark.

 

© Pfizer 2023. Alle rettigheder til denne hjemmeside forbeholdes Pfizer ApS.

12 August 2025 * PP-LGF-DNK-0008
Du forlader nu Pfizer
Du forlader nu et Pfizer-drevet website. Links til alle eksterne websites leveres som en ressource til vores besøgende. Pfizer påtager sig intet ansvar for indholdet af websites, der ikke ejes og drives af Pfizer.